GenSight Biologics Reports its Cash Position as of December 31, 2018

GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics enrolls first subject in first-in-man PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa

GenSight Biologics Reports its Cash Position as of September 30, 2018

GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to present REVERSE data with GS010 at the 2018 Annual Meeting of the American Academy of Ophthalmology

GenSight Biologics to participate in multiple upcoming investor conferences

GenSight Biologics provides an update on the clinical and regulatory pathways for GS010

GenSight Biologics Reports Interim Financial Results for the First Half of 2018

Key Opinion Leaders highlight GS010 efficacy and patient benefits in discussion of findings from REVERSE Phase III clinical trial